EA018225B1 - Соединения оксадиазоантрацена для лечения диабета - Google Patents

Соединения оксадиазоантрацена для лечения диабета Download PDF

Info

Publication number
EA018225B1
EA018225B1 EA201071045A EA201071045A EA018225B1 EA 018225 B1 EA018225 B1 EA 018225B1 EA 201071045 A EA201071045 A EA 201071045A EA 201071045 A EA201071045 A EA 201071045A EA 018225 B1 EA018225 B1 EA 018225B1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
diazaanthracene
oxa
oxo
hexahydro
Prior art date
Application number
EA201071045A
Other languages
English (en)
Russian (ru)
Other versions
EA201071045A1 (ru
Inventor
Аднан М.М. Мджалли
Дхарма Рао Полисетти
Томас Скотт Йокум
Калпати Сантош
Мустафа Гузель
Кристофер Бем
Стефен Томас Дэвис
Original Assignee
Транстек Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Транстек Фарма, Инк. filed Critical Транстек Фарма, Инк.
Publication of EA201071045A1 publication Critical patent/EA201071045A1/ru
Publication of EA018225B1 publication Critical patent/EA018225B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA201071045A 2008-03-07 2009-03-06 Соединения оксадиазоантрацена для лечения диабета EA018225B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (en) 2008-03-07 2009-03-06 Oxadiazoanthracene compounds for the treatment of diabetes

Publications (2)

Publication Number Publication Date
EA201071045A1 EA201071045A1 (ru) 2011-02-28
EA018225B1 true EA018225B1 (ru) 2013-06-28

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071045A EA018225B1 (ru) 2008-03-07 2009-03-06 Соединения оксадиазоантрацена для лечения диабета

Country Status (17)

Country Link
US (7) US7727983B2 (enExample)
EP (1) EP2262364B1 (enExample)
JP (1) JP5382952B2 (enExample)
KR (1) KR101616737B1 (enExample)
CN (1) CN101959405B (enExample)
AU (1) AU2009221722B2 (enExample)
BR (1) BRPI0910282A2 (enExample)
CA (1) CA2716664C (enExample)
DK (1) DK2262364T3 (enExample)
EA (1) EA018225B1 (enExample)
ES (1) ES2567451T3 (enExample)
IL (1) IL207570A (enExample)
MA (1) MA32175B1 (enExample)
MX (1) MX2010009752A (enExample)
NZ (1) NZ587343A (enExample)
WO (1) WO2009111700A2 (enExample)
ZA (1) ZA201006367B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2262364T3 (en) 2008-03-07 2016-03-21 Vtv Therapeutics Llc Oxadiazoanthracenforbindelser for the treatment of diabetes
ES2553645T3 (es) 2009-03-30 2015-12-10 Vtv Therapeutics Llc Derivados sustituidos de azoantraceno, composiciones farmacéuticas y métodos de uso de los mismos
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
WO2012096824A1 (en) * 2011-01-12 2012-07-19 Transtech Pharma, Inc. Phenylglyoxylic acid derivatives and their preparation and use
AU2012215114B2 (en) 2011-02-08 2016-05-12 Pfizer Inc. Glucagon receptor modulator
EP2734503B1 (en) 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ,エルエルシー 小分子glp1rアゴニストのトリス(ヒドロキシメチル)アミノメタン塩ならびにその医薬組成物および使用
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
SG10201704716XA (en) 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
CA2955836C (en) * 2014-07-25 2023-02-14 Celgene International Ii Sarl Glp-1 receptor modulators
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
WO2019217165A1 (en) 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CR20210562A (es) * 2019-04-12 2022-02-18 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
EP4141008A4 (en) 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
EP4130005A4 (en) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
WO2021238964A1 (zh) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 一种glp-1受体激动剂游离碱的制备方法
CN115667219B (zh) * 2020-05-28 2024-11-15 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
AU2021306414A1 (en) 2020-09-01 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused imidazole derivative, preparation method therefor, and medical use thereof
US20250263402A1 (en) 2020-10-12 2025-08-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Benzimidazolone glp-1 receptor agonist and use thereof
CA3195264A1 (en) * 2020-10-14 2022-04-21 Wenge Zhong Crystal forms of glp-1r agonists and uses thereof
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022111624A1 (zh) 2020-11-27 2022-06-02 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するglp-1受容体作動薬を含有する医薬組成物
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
AU2022300055A1 (en) 2021-06-24 2024-01-18 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1 receptor agonist and composition and use thereof
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
JPWO2024063143A1 (enExample) 2022-09-22 2024-03-28
US12234236B1 (en) 2023-09-14 2025-02-25 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
US20040019072A1 (en) * 1995-10-06 2004-01-29 Stacie Canan-Koch Dimer-selective RXR modulators and methods for their use
US6770656B2 (en) * 2000-02-15 2004-08-03 Applied Research Systems Ars Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd 1,4−ベンゾオキサジン誘導体,その製造法およびそれを含有する医薬用組成物
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
RU2256661C2 (ru) * 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
MXPA05010137A (es) * 2003-03-26 2005-11-16 Actelion Pharmaceuticals Ltd Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
DK2262364T3 (en) * 2008-03-07 2016-03-21 Vtv Therapeutics Llc Oxadiazoanthracenforbindelser for the treatment of diabetes
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のglp−1受容体安定化薬および調節薬

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789675A (en) * 1986-02-11 1988-12-06 Takeda Chemical Industries, Ltd. 1,4-benzoxazine derivatives and pharmaceutical use
US20040019072A1 (en) * 1995-10-06 2004-01-29 Stacie Canan-Koch Dimer-selective RXR modulators and methods for their use
US6770656B2 (en) * 2000-02-15 2004-08-03 Applied Research Systems Ars Holding N.V. Amine derivatives for the treatment of apoptosis
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose

Also Published As

Publication number Publication date
US20140187769A1 (en) 2014-07-03
CA2716664A1 (en) 2009-09-11
US20090306063A1 (en) 2009-12-10
US8524708B2 (en) 2013-09-03
US20130317015A1 (en) 2013-11-28
KR101616737B1 (ko) 2016-05-02
US20100197677A1 (en) 2010-08-05
EP2262364A2 (en) 2010-12-22
US9120813B2 (en) 2015-09-01
DK2262364T3 (en) 2016-03-21
IL207570A0 (en) 2010-12-30
ZA201006367B (en) 2011-05-25
US8933222B2 (en) 2015-01-13
JP2011513431A (ja) 2011-04-28
MA32175B1 (fr) 2011-03-01
US20110039837A1 (en) 2011-02-17
AU2009221722A1 (en) 2009-09-11
US7906507B2 (en) 2011-03-15
WO2009111700A3 (en) 2010-03-04
CN101959405A (zh) 2011-01-26
US7790714B2 (en) 2010-09-07
EA201071045A1 (ru) 2011-02-28
EP2262364B1 (en) 2016-03-02
MX2010009752A (es) 2010-09-30
NZ587343A (en) 2012-05-25
IL207570A (en) 2014-03-31
KR20100131455A (ko) 2010-12-15
US8703766B2 (en) 2014-04-22
EP2262364A4 (en) 2012-04-04
US20100324033A1 (en) 2010-12-23
BRPI0910282A2 (pt) 2015-09-01
WO2009111700A2 (en) 2009-09-11
AU2009221722B2 (en) 2014-12-18
US20150087640A1 (en) 2015-03-26
CA2716664C (en) 2016-10-11
ES2567451T3 (es) 2016-04-22
HK1148435A1 (en) 2011-09-09
US7727983B2 (en) 2010-06-01
JP5382952B2 (ja) 2014-01-08
CN101959405B (zh) 2014-07-02

Similar Documents

Publication Publication Date Title
EA018225B1 (ru) Соединения оксадиазоантрацена для лечения диабета
EP2413693B1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
UA102730C2 (uk) Композиція і спосіб застосування похідних арилпіперазину
CN104244939A (zh) 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CA2965467A1 (en) Kcnq2-5 channel activator
KR20140048239A (ko) 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
ES2866324T3 (es) Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria
WO2016061393A1 (en) Fumarate compounds, pharmaceutical compositions, and methods of use
WO2024217528A1 (zh) 一种杂环化合物及其在医药上的应用
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
CN102952072B (zh) 角蒿酯碱类似物及其制备方法和在镇痛药物中的应用
HK1148435B (en) Oxadiazoanthracene compounds for the treatment of diabetes
CN101460474A (zh) 作为钾通道开放剂的3,4-二氨基-3-环丁烯-1,2-二酮衍生物
TW202235079A (zh) 顆粒蛋白前體調節劑及其使用方法

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU